Figure 7: The levels of IL-4 after treatment with 1,25(OH)2D3, MTX, and 1,25(OH)2D3 plus MTX in RA patients. The RA patients’ PBMCs are treated with either anti-CD3/CD28, 1,25(OH)2D3 and MTX at various concentrations, or the combination of 1,25(OH)2D3 and MTX (D2M2 group). 1,25(OH)2D3, MTX and 1,25(OH)2D3 plus MTX up-regulated the level of IL-4; however, there was no significant difference in IL-4 expression in the groups of 1,25(OH)2D3, MTX but there was significant difference in D2 M2 group ( ).